Eli Lilly to Acquire CrossBridge Bio for ADC Platform
Houston, Texas, U.S. | April 15, 2026 Eli Lilly and Company has announced a strategic agreement to acquire CrossBridge...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Houston, Texas, U.S. | April 15, 2026 Eli Lilly and Company has announced a strategic agreement to acquire CrossBridge...
INCHEON, South Korea & ROCKVILLE, Maryland, USA — March 31, 2026 Samsung Biologics has officially completed the acquisition of...
CAMBRIDGE, Mass. & WALTHAM, Mass., USA — March 31, 2026 In a major biopharmaceutical industry consolidation, Biogen Inc. has...
RAHWAY, New Jersey & FOSTER CITY, California, March 25, 2026 Merck & Co. has announced a definitive agreement to...
Parsippany, New Jersey, USA | March 19, 2026 Embecta Corp. has announced a definitive agreement to acquire Owen Mumford...
Montreal, Canada | January 29, 2026 — Repare Therapeutics Inc., a clinical-stage precision oncology company, has completed its previously...
COPENHAGEN, Denmark – December 12, 2025 — Genmab has completed its tender offer to acquire outstanding common shares of...
MUMBAI, December 9, 2025 — Leo Dryfruits & Spices Trading Limited, a leading Indian company in premium dry fruits,...
AUSTIN, Texas — December 5, 2025 — Natera has announced the acquisition of Foresight Diagnostics, a precision oncology company...
Dateline Introduction San Diego, CA & Toronto, Canada — November 19, 2025 — Aptose Biosciences Inc. has entered into...
